Cerebrolysin — Reference, Dosing & Cited Studies

What it is

Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins. It is recognised for neuroprotective and cognitive-enhancing effects via promotion of neuronal growth and repair, BDNF support, and reduction of neuroinflammation. It is widely used internationally for stroke recovery, vascular dementia, and traumatic brain injury rehabilitation.

Mechanism of action

Mixture of low-molecular-weight neuropeptides and amino acids that mimic endogenous neurotrophic factors. Modulates neurogenesis, synaptic plasticity, and BDNF/NGF signalling; reduces glutamate excitotoxicity and microglial inflammation.

Half-life: Cleared within hours — daily IV/IM dosing for therapeutic courses.

Evidence summary

Multiple Cochrane and meta-analytic reviews support modest benefits in acute ischemic stroke recovery and vascular dementia. Trauma and TBI animal data show cognitive recovery; mood and anxiety pilot work is encouraging but small.

Typical dosing protocols

Typical dose

5000–30000 mcg

Frequency

Once daily

Cycle length

4 weeks

5–30 ml IV/IM daily for 10–20 days as a course
Repeat 1–2 courses per year
Often combined with structured rehabilitation

Side effects & safety

Generally well-tolerated; mild headache, agitation, or sweating possible
Allergic reactions rare — porcine origin
Avoid in status epilepticus or severe renal failure

Cited studies

Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.